Publications by CIRM Staff

• Trounson A, Shepard KA, DeWitt ND. Human disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev. 2012 Oct;22(5):509-16.
• Patel R, Lomax G (2011) Use of hESC Lines by CIRM Grantees: The Value of Embryonic Stem Cell Research Oversight (ESCRO) Committees. J Stem Cell Res Ther 1:107.
• Lomax GP, Trounson AO. Correcting misperceptions about cryopreserved embryos and stem cell research. Nat Biotechnol. 2013 Apr;31(4):288-90.
• Lomax GP, Shepard KA. Return of results in translational iPS cell research: considerations for donor informed consent.Stem Cell Res Ther. 2013 Jan 21;4(1):6.
  
• Lomax GP. The Great ESCRO Experiment: There Is Still Value to Be Gained. Am J Bioeth. 2013 Jan;13(1):55-6
• Feigal EG, Tsokas K, Zhang J, Cromer MV, Whittlesey KJ, Werner MJ. Perspective: communications with the Food and Drug Administration on the development pathway for a cell-based therapy: why, what, when, and how? Stem Cells Transl Med. 2012 Nov;1(11):825-32.
• Whittlesey KJ, Witten C. US FDA outreach to the regenerative medicine community: challenges and opportunities. Regen Med. 2012 Jul;7(4):595-603.
• Frey-Vasconcells J, Whittlesey KJ, Baum E, Feigal EG. Translation of stem cell research: points to consider in designing preclinical animal studies. Stem Cells Transl Med. 2012 May;1(5):353-8.
• DeWitt ND, Trounson A. Direct conversion in the heart: a simple twist of fate. EMBO J. 2012 Apr 20;31(10):2244-6
• Trounson A, Dewitt ND. Stem cell biology: Towards the reality of cell therapeutics. Nat Cell Biol. 2012 Apr 2;14(4):331
• Trounson A. California institute for regenerative medicine: accelerating stem cell therapies in California and beyond. Stem Cells. 2012 Mar;30(3):357-9
• Dewitt ND, Yaffe MP, Trounson A. Building stem-cell genomics in California and beyond. Nat Biotechnol. 2012 Jan 9;30(1):20-5
• Trounson A, Grieshammer U. (2012) Chimeric primates: embryonic stem cells need not apply. Cell. 2012 Jan 20;148(1-2):19-21
• Koch NJ, Baum E, Trounson A. (2011) European court ruling on embryonic stem cells: ripple effects. Cell Stem Cell. 2011 Dec 2;9(6):499-500
• Lyrawati D, Trounson A, Cram D. (2011) Expression of GFP in the mitochondrial compartment using DQAsome-mediated delivery of an artificial mini-mitochondrial genome. Pharm Res. Nov;28(11):2848-62.
• Adams A, Lomax G, Sanatarini A (2011) Social media and stem cell science: examining the discourse. Regen Med. 6(6SuppL.):121-124.
• Grieshammer U, Shepard KA, Nigh A,Trounson AO (2011) Finding the niche for human somatic cell nuclear transfer. Nature Biotech 2011 Aug 5;29(8):701-5.
• Lomax, G.P., Peckman, S.R. (2011) Stem Cell Policy Exceptionalism: Proceed with Caution. Stem Cell Reviews and Reports. Vol. 5, No. 1.
• Robson J, Trounson A (2011) The potential of stem cells for 21st century neuroscience. Special Issue: Stem Cells in Neuroscience. Neurochem Int. Sep;59(3):327-8.
• Trounson A (2011) CIRM the way ahead. Regen Med. May;6(3):285-90.
• Trounson A, Baum E (2011) Regulatory Challenges – The Survey Says. EBR (in press)
• Trounson A, DeWitt N, Feigal EG (2011) A New Model Needed for the Delivery of Stem Cell Therapies in Translation for Regenerative Medicine – The Alpha Stem Cell Clinic. Stem Cells Translation Med (in press)
• Trounson A, Thakar R, Lomax G, Gibbons D (2011) Clinical trials for stem cell therapies. BMC Med. 2011 May 10;9(1):52.
• Carson S, Eschenbach D, Lomax G, Rice V, Sauer M, Taylor R (2010) Proposed oocyte donation guidelines for stem cell research. ASRM Fertility and Sterility. Vol 94, No7.
• Klein R N , Trounson A (2010) A new political-financial paradigm for medical research: the California model. . In C. Prescott and I Polak, eds., The Delivery of Regenerative Medicines and Their Impact on Healthcare. London: Taylor & Francis Group, LLC pp 11-33.
• Lomax, G.P. (2010) Stem Cell Research: A Platform for Science-Policy Innovation. Stanford Journal of Law, Science and Policy. March 2010
• Lomax, G.P. (2010) Rejuvenated Federalism: State-Based Stem Cell Research Policy. In Contested Cells: Global Perspectives on the Stem Cell Debate: Capps B.J., Campbell A.V.editors.
• Trounson A, Baum E, Gibbons D, Tekamp-Olson P (2010) Developing a model for successful translation of stem cell therapies. Cell Stem Cell 6(6):513-6.
• Martell K, Trounson A, Baum E (2010) Stem cell therapies in clinical trials: Workshop on best practices and the need for harmonization. Cell Stem Cell 7(4):451-4
• Tekamp-Olson P, Canet-Aviles, Collins L R, Steffen B J, Talib S, Trounson A (2010) Challenges in taking embryonic stem cells from bench to clinic. In: Stem Cells From Bench to Bedside (Second Edn) A Bongso, E H Lee eds.
• Trounson A.(2010) Law, Ethics, Religion, and Clinical Translation in the 21st Century. Stem Cells. Jan 8;28(1):2.
• Trounson A (2009) Rats, Cats, and elephants, but still no unicorn: Induced pluripotent stem cells from new species. Cell Stem Cell. Jan 9;4(1):3-4.
• Trounson A (2009) New perspectives in human stem cell therapeutic research. BMC Med. 2009 Jun 11;7:29-33.
• Lomax, G.P., McNab, A. (2008) Harmonizing Standards and Coding for hESC Research. Cell Stem Cell 2, March.
• Lomax, G.P., Stayn S., (2008) Similarities and Differences Among Stem Cell Research Policies: Opportunities for Policymakers, Patients, and Researchers. Medical Research Law and Policy.11-5-08.
• Trounson A. (2008) Integration and translation: driving stem cell therapies toward the clinic. Regen Med. May;3(3):269-73.
• Trounson A, Klein R, Murphy R (2008) Stem cell research in California: the game is on. Cell Feb 22;132(4):522-4.
• Lomax, G.P., Hall, Z.W., Lo B. (2007) Responsible Oversight of Human Stem Cell Research: The California Institute for Regenerative Medicine’s Medical and Ethical Standards. PLOS Medicine May 2007, Volume 4. Issue 5 e114.